Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)
Get Alerts OSTX Hot Sheet
Join SI Premium – FREE
Dallas, Texas--(Newsfile Corp. - September 8, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners initiates their coverage on OS Therapies Inc. (NYSEAmerican: OSTX). OS Therapies advanced meaningful clinical, regulatory, and financial milestones in 2Q25 as it moves closer to bringing OST-HER2 to patients with recurrent, fully resected, pulmonary metastatic osteosarcoma. Importantly, the FDA confirmed that OST-HER2 meets the biological definition of a Regenerative Medicine Advanced Therapy (RMAT) and issued a Biologics License Application (BLA) number in preparation for an Accelerated Approval submission. Final 12-month Event Free Survival (EFS) results from the Phase 2b trial demonstrated statistically significant improvement, supported by interim 2-year Overall Survival (OS) data, further validating the clinical benefit. With a U.S. commercial partnership secured with Eversana, OS Therapies is positioning for a potential U.S. launch in the first half of 2026.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Following a successful FDA End of Phase 2 meeting, OSTX is on track to begin rolling BLA submission for OST-HER2 in September 2025.
- Phase 2b trial showed statistically significant improvements in 12-month Event Free Survival (35% vs. 20%) and interim 2-year Overall Survival (66.6% vs. 40%), with an excellent safety profile.
- Completed warrant exchange financings raising ~$7.9M in Q3, extending cash runway into 2027 and funding commercial launch preparations.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
[email protected]
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265606
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Waymo Explores Split With Uber - FT
- Freedom Broker Downgrades Gentherm Incorporated (THRM) to Hold
- General Dynamics wins $400M space contract
Create E-mail Alert Related Categories
Newsfile, Press ReleasesRelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share